In order to improve the efficacy of immunotherapy, Chamoto et al. showed that metabolic activators of AMPK, mTOR, and PGC1α synergize with PD-1 blockade in mouse models, inducing mitochondrial biogenesis, promoting FAO and OXPHOS, upregulating Bcl2, and generating long-lived effector memory cells, thus leading to tumor regression [267,268]. Here, PRKAA1 is linked to neoplasm.